Zoetis ZTS · NYSE
$79.76 +0.48% (+$0.38)
Summary
80 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 27 USD is left as net profit.
- It earns 22 USD a year on every 100 USD of invested capital.
- It has raised its dividend 12 years in a row and pays out only 33% of profit.
- The share price is below the Bulios Fair Price.
What to watch
- For every 100 USD of shareholders' equity it carries 293 USD of debt.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 12.5 USD for 1 USD of yearly profit. Over the last five years it was 35.9 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 7.2% a year over 5 years. Over the last 3 years it grew by 5.4% a year. For the next fiscal year analysts expect revenue to fall by 2.1%. Earnings per share grew by 10% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 29 USD
- Research and development 7.6 USD
- Sales and administration 26 USD
- Taxes and other 9.5 USD
- Net profit 27 USD
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 USD
Out of every 100 USD of revenue, 27 USD is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 3.9 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, safe- Yield
- 2.63%
- Paid out of profit
- 33%
- Raised in a row
- 12 years
You receive $2.09 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Neutral- Buy 15
- Hold 17
- Sell 0
Today's price within the analysts' price targets
The average target of $87.33 is 9.4% above today's price. 47% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Horses 68%
- Cattle 16%
- Swine 5.0%
- Poultry 4.7%
- Dogs and Cats 3.3%
- Other 3.1%
By region
- United States Segment 55%
- International Segment 45%
Horses brings in 68% of revenue.
Segments in detail